Kiniksa Pharmaceuticals International, plc (KNSA)
(Delayed Data from NSDQ)
$37.01 USD
-0.28 (-0.75%)
Updated Oct 31, 2025 03:59 PM ET
After-Market: $36.98 -0.03 (-0.08%) 7:58 PM ET
5-Strong Sell of 5 5
F Value A Growth C Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Kiniksa Pharmaceuticals International, plc's return on equity, or ROE, is 7.46% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.03%. While this shows that KNSA makes good use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
KNSA 37.01 -0.28(-0.75%)
Will KNSA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for KNSA
New Strong Sell Stocks for Oct. 30th
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again
Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Other News for KNSA
Is KNSA building bullish momentum? 50 Day Moving Average Support shows up after sinking 0.75%
Boomer Sell Setup appears for KNSA after 0.24% move
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage
TANG CAPITAL MANAGEMENT LLC Increases Stake in Immunocore Holdings PLC
Is KNSA preparing to trend lower? Fell Below 20 Day Moving Average shows up after crashing 5.2%